而在欧洲，2000年至2014年间51%的新批准药品是已有药品的改良版，因此并不能带来附加的健康收益。
And in Europe between 2000 and 2014, 51% of newly approved drugs were modified versions of existing medicines, and thus offered no additional health benefits.